United States: Abbott Labs, Inc. on Thursday, 18^th May 2023 announced that it has received its first Premarket Approval (PMA) for its companion monitoring device for checking irregular heartbeat. Assert – IQ ICM which has a significant advancement among the tools which are currently available in the market for the diagnosis of irregular heartbeats. This device is inserted under the skin and patients can lead a normal life like others. This device can detect hard-to-spot irregularities and also help doctors to determine a treatment course. This device has a small Bluetooth which is designed to connect with a transmitter of the person’s cell phone and by using this connectivity a person can check heartbeats every 20 seconds. According to the Centers for Disease Control and Prevention, about 695,000 people in the United States died from heart disease in 2021 and every year, about 805,000 people in the United States have a heart attack.

Assert-IQ offers two choices with battery lives of at least three or six years, whereas many commercially marketed ICMs only monitor a person's heart rhythm for a short period of time. This gives clinicians new levels of flexibility in diagnostic monitoring. A device with at least six years of battery life gives doctors the ability to monitor over a longer period of time, even though the three-year option could be chosen for more conventional monitoring such as detecting collapse, heart palpitations, or the detection of irregular cardiac rhythms. When caring for patients who are receiving therapy, have recently undergone a cardiac ablation operation, or are at risk of developing new arrhythmias like atrial fibrillation, this surveillance can be particularly crucial.

According to the Divisional Vice President of Medical Affairs and Chief Medical Officer of Abbott's Cardiac Rhythm Management Business, “As the incidence of abnormal heart rhythms like atrial fibrillation continue to rise, more doctors are turning to ICM technology to monitor their patients remotely to better detect the cause of symptoms that can impact overall health and quality of life. Until now, insertable cardiac monitors have allowed for remote monitoring of patients but lacked the longevity needed to monitor them long-term. Abbott's Assert-IQ ICM offers physicians a connected health device that will help them provide the best care for their patients while making more accurate and informed treatment decisions.”

According to TechSci Research, product launches play a major role in companies’ growth to maintain a strong market position. Among other companies Abbott launched product insertable cardiac monitoring device can grow demand in the forecast period due to automatic detection and record of abnormal heart rhythms, such as atrial fibrillation, bradycardia, tachycardia, or pauses in the heart's electrical activity and wireless technology which will help the company’s growth in a particular sector to promote their products. . Product launches help to build the company’s value, aware people of their products and offers. This can give them a better opportunity to enter the healthcare industry for attracting potential consumers, investors as well as competitors. If the company makes some innovative offers to address the needs of the market, then they can gain customers the attraction of those who are looking for the best products. The pre-approval of the Assert-IQ insertable cardiac monitor device has been made by Abbott Lab, a medical device company and one of the largest medical device company in the world. This company is collaborating with other pharmaceutical and medical device companies for promoting their products.